
Commentary|Articles|April 29, 2026
Staging Pitfalls, Biomarker-Guided Care, and Emerging Targets in Esophageal Cancer: Your Clinical Questions Answered
Author(s)Courtney Flaherty
Fact checked by: Kyle Doherty
Peter Enzinger, MD, discusses diagnostic pathways, the role of surgery, and ongoing trials of interest in esophageal cancer in this clinician-focused FAQ.
Advertisement
Advertisement
During Esophageal Cancer Awareness Month, OncLive® sat down with Peter Enzinger, MD, to break down and address key areas of uncertainty encountered in routine practice. The following FAQ, adapted from this conversation, provides insights into the clinical nuances shaping contemporary esophageal cancer diagnosis and management, including diagnostic and staging pitfalls, the role of curative-intent surgery and chemoradiation, and emerging biomarker-driven approaches of interest.
Related to this article

Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.

Lirafugratinib was added as a category 2A subsequent-line option for cholangiocarcinoma with an FGFR2 fusion or rearrangement and disease progression.

The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.
Advertisement
Advertisement


